Proteomics in Cancer

Advances in Clinical Chemistry

Volumn 44, Issue , 2007, Pages 103-142

  Reymond, M A ^a   Schlegel, W ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

BODY FLUID; CHEMISTRY; EARLY DIAGNOSIS; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; PROGNOSIS; PROTEOMICS; REVIEW;

BODY FLUIDS; EARLY DIAGNOSIS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 34347217393     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(07)44004-5     Document Type: Review

References (141)

1. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 3 (2005) 481-488
2. Adams G., and Weiner L. Monoclonal antibody therapy of cancer. Nat Biotechnol 23 9 (2005) 1147-1157 Review.
3. Nygren P., Sorbye H., Osterlund P., and Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 44 3 (2005) 203-217 Review.
4. Sanborn R., and Blanke C. Gastrointestinal stromal tumors and the evolution of targeted therapy. Clin Adv Hematol Oncol 3 8 (2005) 647-657 Review.
5. Lakhani S., and Ashworth A. Microarray and histopathological analysis of tumours: The future and the past?. Nat Rev Cancer 1 2 (2001) 151-157 Review.
6. Anderson L., and Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18 3-4 (1997) 533-537
7. Hwang D., Smith J., Leslie D., Weston A., Rust A., Ramsey S., et al. A data integration methodology for systems biology: Experimental verification. Proc Natl Acad Sci USA 102 48 (2005) 17302-17307
8. Vogel T., Zhuang Z., Li J., Okamoto H., Furuta M., Lee Y., et al. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 11 10 (2005) 3624-3632
9. Ott V., Guenther K., Steinert R., Tortola S., Borisch B., Schlegel W., et al. Accuracy of two-dimensional electrophoresis for target discovery in human colorectal cancer. Pharmacogenomics J 1 2 (2001) 142-151
10. Reymond M., Sanchez J., Schneider C., Rohwer P., Tortola S., Hohenberger W., et al. Specific sample preparation in colorectal cancer. Electrophoresis 18 3-4 (1997) 622-624
11. Lexander H., Franzen B., Hirschberg D., Becker S., Hellstrom M., Bergman T., et al. Differential protein expression in anatomical zones of the prostate. Proteomics 5 10 (2005) 2570-2576
12. Craven R., and Banks R. Laser capture microdissection and proteomics: Possibilities and limitation. Proteomics 1 10 (2001) 1200-1204 Review.
13. Zhang D., Tai L., Wong L., Sethi S., and Koay E. Proteomics of breast cancer: Enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 5 7 (2005) 1797-1805
14. Lawrie L., and Curran S. Laser capture microdissection and colorectal cancer proteomics. Methods Mol Biol 293 (2005) 245-253
15. Shekouh A., Thompson C., Prime W., Campbell F., Hamlett J., Herrington C., et al. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 3 10 (2003) 1988-2001
16. Reymond M., Sanchez J., Hughes G., Gunther K., Riese J., Tortola S., et al. Standardized characterization of gene expression in human colorectal epithelium by two-dimensional electrophoresis. Electrophoresis 18 15 (1997) 2842-2848
17. Ebert M., Kruger S., Fogeron M., Lamer S., Chen J., Pross M., et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5 6 (2005) 1693-1704
18. Kellner U., Steinert R., Seibert V., Heim S., Kellner A., Schulz H., et al. Epithelial cell preparation for proteomic and transcriptomic analysis in human pancreatic tissue. Pathol Res Pract 200 2 (2004) 155-163
19. Pieper R., Gatlin C., Makusky A., Russo P., Schatz C., Miller S., et al. The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 3 7 (2003) 1345-1364
20. Banks R., Stanley A., Cairns D., Barrett J., Clarke P., Thompson D., et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51 9 (2005) 1637-1649
21. Righetti P., Castagna A., Antonucci F., Piubelli C., Cecconi D., Campostrini N., et al. Proteome analysis in the clinical chemistry laboratory: Myth or reality?. Clin Chim Acta 357 2 (2005) 123-139
22. Tantipaiboonwong P., Sinchaikul S., Sriyam S., Phutrakul S., and Chen S. Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics 5 4 (2005) 1140-1149
23. Wattiez R., and Falmagne P. Proteomics of bronchoalveolar lavage fluid. J Chromatogr B Analyt Technol Biomed Life Sci 815 1-2 (2005) 169-178
24. Alexander H., Stegner A., Wagner-Mann C., Du Bois G., Alexander S., and Sauter E. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 10 22 (2004) 7500-7510
25. Gronborg M., Bunkenborg J., Kristiansen T., Jensen O., Yeo C., Hruban R., et al. Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3 5 (2004) 1042-1055
26. Kristiansen T., Bunkenborg J., Gronborg M., Molina H., Thuluvath P., Argani P., et al. A proteomic analysis of human bile. Mol Cell Proteomics 3 7 (2004) 715-728
27. Wilkins M., Sanchez J., Williams K., and Hochstrasser D. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis 17 5 (1996) 830-838
28. Griffin T., Han D., Gygi S., Rist B., Lee H., Aebersold R., et al. Toward a high-throughput approach to quantitative proteomic analysis: Expression-dependent protein identification by mass spectrometry. J Am Soc Mass Spectrom 12 12 (2001) 1238-1246
29. Wright Jr. G. SELDI proteinchip MS: A platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2 6 (2002) 549-563 Review.
30. Schulz-Knappe P., Zucht H., and Schrader M. Differential peptide display. In: Gaenschirt D., Harms F., Rohmann S., and Schulz-Knappe P. (Eds). Peptidomics in Drug Development (2005), Editio Cantor, Aulendorf, Germany 33-35
31. Byrd J., and Bresalier R. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 23 1-2 (2004) 77-99 Review.
32. Zamfir A., Vakhrushev S., Sterling A., Niebel H., Allen M., and Peter-Katalinic J. Fully automated chip-based mass spectrometry for complex carbohydrate system analysis. Anal Chem 76 7 (2004) 2046-2054
33. Posadas E., Simpkins F., Liotta L., MacDonald C., and Kohn E. Proteomic analysis for the early detection and rational treatment of cancer-realistic hope?. Ann Oncol 16 1 (2005) 16-22 Review.
34. Haab B. Methods and applications of antibody microarrays in cancer research. Proteomics 3 11 (2003) 2116-2122 Review.
35. Uhlen M., and Ponten F. Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 4 4 (2005) 384-393 Review.
36. Righetti P., Castagna A., Antonucci F., Piubelli C., Cecconi D., Campostrini N., et al. Proteome analysis in the clinical chemistry laboratory: Myth or reality?. Clin Chim Acta 357 2 (2005) 123-139
37. Meyerson M., and Carbone D. Genomic and proteomic profiling of lung cancers: Lung cancer classification in the age of targeted therapy. J Clin Oncol 23 14 (2005) 3219-3226 Review.
38. Franzen B., Iwabuchi H., Kato H., Lindholm J., and Auer G. Two-dimensional polyacrylamide gel electrophoresis of human lung cancer: Qualitative aspects of tissue preparation in relation to histopathology. Electrophoresis 12 7-8 (1991) 509-515
39. Okuzawa K., Franzen B., Lindholm J., Linder S., Hirano T., Bergman T., et al. Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 15 3-4 (1994) 382-390
40. Bergman A., Benjamin T., Alaiya A., Waltham M., Sakaguchi K., Franzen B., et al. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21 3 (2000) 679-686
41. Zhukov T., Johanson R., Cantor A., Clark R., and Tockman M. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 40 3 (2003) 267-279
42. Xiao X., Liu D., Tang Y., Guo F., Xia L., Liu J., et al. Development of proteomic patterns for detecting lung cancer. Dis Markers 19 1 (2003-2004) 33-39
43. Yang S., Xiao X., Zhang W., Zhang L., Zhang W., Zhou B., et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5 (2005) 83
44. Ueda K. Proteome analysis of autoantibodies in sera of patients with cancer. Rinsho Byori 53 5 (2005) 437-445
45. Hirano T., Franzen B., Uryu K., Okuzawa K., Alaiya A., Vanky F., et al. Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma. Br J Cancer 72 4 (1995) 840-848
46. Rajapakse J., Duan K., and Yeo W. Proteomic cancer classification with mass spectrometry data. Am J Pharmacogenomics 5 5 (2005) 281-292 Review.
47. Li C., Zhan X., Li M., Wu X., Li F., Li J., et al. Proteomic comparison of two-dimensional gel electrophoresis profiles from human lung squamous carcinoma and normal bronchial epithelial tissues. Genomics Proteomics Bioinformatics 1 1 (2003) 58-67
48. Li C., Chen Z., Xiao Z., Wu X., Zhan X., Zhang X., et al. Comparative proteomics analysis of human lung squamous carcinoma. Biochem Biophys Res Commun 309 1 (2003) 253-260
49. Wu X., Xiao Z., Chen Z., Li C., Li J., Feng X., et al. Differential analysis of two-dimension gel electrophoresis profiles from the normal-metaplasia-dysplasia-carcinoma tissue of human bronchial epithelium. Pathol Int 54 10 (2004) 765-773
50. Sueoka E., Sueoka N., Goto Y., Matsuyama S., Nishimura H., Sato M., et al. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res 61 5 (2001) 1896-1902
51. Iwanaga K., Sueoka N., Sato A., Hayashi S., and Sueoka E. Heterogeneous nuclear ribonucleoprotein B1 protein impairs DNA repair mediated through the inhibition of DNA-dependent protein kinase activity. Biochem Biophys Res Commun 333 3 (2005) 888-895
52. Chen G., Gharib T., Huang C., Thomas D., Shedden K., Taylor J., et al. Proteomic analysis of lung adenocarcinoma: Identification of a highly expressed set of proteins in tumors. Clin Cancer Res 8 7 (2002) 2298-2305
53. Hirano T., Fujioka K., Franzen B., Okuzawa K., Uryu K., Shibanuma H., et al. Relationship between TA01 and TA02 polypeptides associated with lung adenocarcinoma and histocytological features. Br J Cancer 75 7 (1997) 978-985
54. Gharib T., Chen G., Wang H., Huang C., Prescott M., Shedden K., et al. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 4 5 (2002) 440-448
55. Bergman A., Benjamin T., Alaiya A., Waltham M., Sakaguchi K., Franzen B., et al. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21 3 (2000) 679-686
56. Reymond M., Sanchez J., Hughes G., Gunther K., Riese J., Tortola S., et al. Standardized characterization of gene expression in human colorectal epithelium by two-dimensional electrophoresis. Electrophoresis 18 15 (1997) 2842-2848
57. Reymond M., Steinert R., Kahne T., Sagynaliev E., Allal A., and Lippert H. Expression and functional proteomics studies in colorectal cancer. Pathol Res Pract 200 2 (2004) 119-127 Review.
58. Sagynaliev E., Steinert R., Nestler G., Lippert H., Knoch M., and Reymond M. Web-based data warehouse on gene expression in human colorectal cancer. Proteomics 5 12 (2005) 3066-3078
59. Albrethsen J., Bogebo R., Gammeltoft S., Olsen J., Winther B., and Raskov H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: A biomarker study. BMC Cancer 5 (2005) 8
60. Nam M., Kee M., Kuick R., and Hanash S. Identification of defensin alpha6 as a potential biomarker in colon adenocarcinoma. J Biol Chem 280 9 (2005) 8260-8265
61. Melle C., Osterloh D., Ernst G., Schimmel B., Bleul A., and von Eggeling F. Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. Int J Mol Med 16 1 (2005) 11-17
62. Gu S., Liu Z., Pan S., Jiang Z., Lu H., Amit O., et al. Global investigation of p53-induced apoptosis through quantitative proteomic profiling using comparative amino acid-coded tagging. Mol Cell Proteomics 3 10 (2004) 998-1008
63. Ebert M., Kruger S., Fogeron M., Lamer S., Chen J., Pross M., et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5 6 (2005) 1693-1704
64. Ebert M., Lamer S., Meuer J., Malfertheiner P., Reymond M., Buschmann T., et al. Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res 4 2 (2005) 586-590
65. Rosty C., and Goggins M. Identification of differentially expressed proteins in pancreatic cancer using a global proteomic approach. Methods Mol Med 103 (2005) 189-197
66. Shen J., Person M., Zhu J., Abbruzzese J., and Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64 24 (2004) 9018-9026
67. Koopmann J., Zhang Z., White N., Rosenzweig J., Fedarko N., Jagannath S., et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10 3 (2004) 860-868
68. Yu Y., Chen S., Wang L., Chen W., Guo W., Yan H., et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 68 1 (2005) 79-86 Epub 2005 April 8.
69. Xia Q., Kong X., Zhang G., Hou X., Qiang H., and Zhong R. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 330 2 (2005) 526-532
70. Liang C., Leow C., Neo J., Tan G., Lo S., Lim J., et al. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 5 8 (2005) 2258-2271
71. Takashima M., Kuramitsu Y., Yokoyama Y., Iizuka N., Fujimoto M., Nishisaka T., et al. Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: Association with tumor progression as determined by proteomic analysis. Proteomics 5 6 (2005) 1686-1692
72. Li C., Hong Y., Tan Y., Zhou H., Ai J., Li S., et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics 3 4 (2004) 399-409
73. Yan W., Lee H., Deutsch E., Lazaro C., Tang W., Chen E., et al. A dataset of human liver proteins identified by protein profiling via isotope-coded affinity tag (ICAT) and tandem mass spectrometry. Mol Cell Proteomics 3 10 (2004) 1039-1041
74. Block T., Comunale M., Lowman M., Steel L., Romano P., Fimmel C., et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 102 3 (2005) 779-784
75. Wang J., Zhang B., Yu J., Liu J., Yang M., and Zheng S. Using ANN and serum protein pattern models in liver cancer diagnosis. Zhonghua Yi Xue Za Zhi 85 3 (2005) 189-192 Chinese.
76. Somiari R., Somiari S., Russell S., and Shriver C. Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 815 1-2 (2005) 215-225
77. Luo Y., Zhang J., Liu Y., Shaw A., Wang X., Wu S., et al. Comparative proteome analysis of breast cancer and normal breast. Mol Biotechnol 29 3 (2005) 233-244
78. Celis J., Moreira J., Cabezon T., Gromov P., Friis E., Rank F., et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: Toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics 4 4 (2005) 492-522
79. Li J., Zhang Z., Rosenzweig J., Wang Y., and Chan D. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48 8 (2002) 1296-1304
80. Li J., Orlandi R., White C., Rosenzweig J., Zhao J., Seregni E., et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51 12 (2005) 2229-2235
81. Mathelin C., Cromer A., Wendling C., Tomasetto C., and Rio M. Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res Treat (2005) 1-8
82. Mendrinos S., Nolen J., Styblo T., Carlson G., Pohl J., Lewis M., et al. Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer 105 3 (2005) 178-183
83. Canelle L., Bousquet J., Pionneau C., Deneux L., Imam-Sghiouar N., Caron M., et al. An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Methods 299 1-2 (2005) 77-89
84. Moreira J., Ohlsson G., Rank F., and Celis J. Down-regulation of the tumor suppressor protein 14-3-3 sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 4 4 (2005) 555-569
85. He Q., Zhou Y., Wong E., Ehlen T., Auersperg N., Chiu J., et al. Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies. Gynecol Oncol 98 1 (2005) 68-76
86. Jacobs I., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3 4 (2004) 355-366
87. Petricoin E., Ardekani A., Hitt B., Levine P., Fusaro V., Steinberg S., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
88. Conrads T., Fusaro V., Ross S., Johann D., Rajapakse V., Hitt B., et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 11 (2004) 163-178
89. Sheehan K., Calvert V., Kay E., Lu Y., Fishman D., Espina V., et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4 4 (2005) 346-355 Epub 2005 January 25. Review.
90. Choi Y., Kang S., Hong S., Xie X., and Cho N. Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics 5 6 (2005) 1481-1493
91. Yoshizaki T., Enomoto T., Nakashima R., Ueda Y., Kanao H., Yoshino K., et al. Altered protein expression in endometrial carcinogenesis. Cancer Lett 226 2 (2005) 101-106
92. Guo J., Yang E., Desouza L., Diehl G., Rodrigues M., Romaschin A., et al. A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. Proteomics 5 7 (2005) 1953-1966
93. DeSouza L., Diehl G., Rodrigues M., Guo J., Romaschin A., Colgan T., et al. Search for cancer markers from endometrial tissues using differentially labelled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 4 2 (2005) 377-386
94. Banez L., Srivastava S., and Moul J. Proteomics in prostate cancer. Curr Opin Urol 15 3 (2005) 151-156 Review.
95. Rehman I., Azzouzi A., Catto J., Allen S., Cross S., Feeley K., et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: A pilot study. Urology 64 6 (2004) 1238-1243
96. Kuruma H., Egawa S., Oh-Ishi M., Kodera Y., Satoh M., Chen W., et al. High molecular mass proteome of androgen-independent prostate cancer. Proteomics 5 4 (2005) 1097-1112
97. Anazawa Y., Nakagawa H., Furihara M., Ashida S., Tamura K., Yoshioka H., et al. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res 65 11 (2005) 4578-4586
98. Meehan K., and Sadar M. Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics 4 4 (2004) 1116-1134
99. Lam Y., Mobley J., Evans J., Carmody J., and Ho S. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 5 11 (2005) 2927-2938
100. Le L., Chi K., Tyldesley S., Flibotte S., Diamond D., Kuzyk M., et al. Dentification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51 4 (2005) 695-707
101. Hastie C., Saxton M., Akpan A., Cramer R., Masters J., and Naaby-Hansen S. Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene 24 (2005) 5905-5913
102. Ohlsson G., Moreira J., Gromov P., Sauter G., and Celis J. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 4 4 (2005) 570-581
103. Memon A., Sorensen B., Meldgaard P., Fokdal L., Thykjaer T., and Nexo E. Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin Cancer Res 11 2 Pt 1 (2005) 606-611
104. Cui J., Wang J., He K., Jin B., Wang H., Li W., et al. Two-dimensional electrophoresis protein profiling as an analytical tool for human acute leukemia classification. Electrophoresis 26 1 (2005) 268-279
105. Lin Z., Crockett D., Jenson S., Lim M., and Elenitoba-Johnson K. Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol Cell Proteomics 3 8 (2004) 820-833
106. Caputo E., Lombardi M., Luongo V., Moharram R., Tornatore P., Pirozzi G., et al. Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. J Chromatogr B Analyt Technol Biomed Life Sci 819 1 (2005) 59-66
107. Brouwers F., Petricoin III E., Ksinantova L., Breza J., Rajapakse V., Ross S., et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 12 2 (2005) 263-272
108. Grubb R., Calvert V., Wulkuhle J., Paweletz C., Linehan W., Phillips J., et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3 11 (2003) 2142-2146
109. Oh J., Karlmark K., Shin J., Pollak A., Freilinger A., Hengstschlager M., et al. Differentiation of neuroblastoma cell line N1E-115 involves several signaling cascades. Neurochem Res 30 3 (2005) 333-348
110. Zhang W., Bergamaschi D., Jin B., and Lu X. Posttranslational modifications of p27kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo. Blood 105 9 (2005) 3691-3698
111. Masri F., Comhair S., Koeck T., Xu W., Janocha A., Ghosh S., et al. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med 172 5 (2005) 597-605
112. Myung J., Afjehi-Sadat L., Felizardo-Cabatic M., Slavc I., and Lubec G. Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci 2 1 (2004) 8
113. Yim E., Meoyng J., Namakoong S., Um S., and Park J. Genomic and proteomic expression patterns in HPV-16 E6 gene transfected stable human carcinoma cell lines. DNA Cell Biol 23 12 (2004) 826-835
114. Paron I., D'Ambrosio C., Scaloni A., Berlingieri M., Pallante P., Fusco A., et al. A differential proteomic approach to identify proteins associated with thyroid cell transformation. J Mol Endocrinol 34 1 (2005) 199-207
115. Shin Y., Yoo B., Chang H., Jeon E., Hong S., Jung M., et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65 8 (2005) 3162-3170
116. Sgarra R., Tessari M., Di Bernardo J., Rustighi A., Zago P., Liberatori S., et al. Discovering high mobility group A molecular partners in tumour cells. Proteomics 5 6 (2005) 1494-1506
117. Beckner M., Chen X., An J., Day B., and Pollack I. Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest 85 3 (2005) 316-327
118. Souchelnytskyi S. Proteomics of TGF-beta signaling and its impact on breast cancer. Expert Rev Proteomics 2 6 (2005) 925-935
119. Sandhu C., Connor M., Kislinger T., Slingerland J., and Emili A. Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. J Proteome Res 4 3 (2005) 674-689
120. Hayashi E., Kuramitsu Y., Okada F., Fujimoto M., Zhang X., Kobayashi M., et al. Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 5 4 (2005) 1024-1032
121. Cusick M., Klitgord N., Vidal M., and Hill D. Interactome: Gateway into systems biology. Hum Mol Genet 14 Spec No. 2 (2005) R171-R181
122. Gaenshirt D., and Harms F. The role of peptidomics in drug development. In: Gaenschirt D., Harms F., Rohmann S., and Schulz-Knappe P. (Eds). Peptidomics in Drug Development (2005), Editio Cantor, Aulendorf, Germany 109-133
123. Omenn G., States D., Adamski M., Blackwell T., Menon R., Hermjakob H., et al. Overview of the HUPO plasma proteome project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5 13 (2005) 3226-3245
124. Vitzthum F., Behrens F., Anderson N., and Shaw J. Proteomics: From basic research to diagnostic application. A review of requirements and needs. J Proteome Res 4 4 (2005) 1086-1097 Review.
125. In: Wittekind C., Greene F., Hutter R., Klümpfinger M., and Sobin L. (Eds). TNM Atlas: Illustrated Guide to the TNM Classification of Malignant Tumours. 5th ed (2005), Wiley-Lyss, Hoboken
126. Chen G., Gharib T., Wang H., Huang C., Kuick R., Thomas D., et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 100 23 (2003) 13537-13542
127. Gaenshirt D., and Harms F. The role of peptidomics in drug development. In: Gaenschirt D., Harms F., Rohmann S., and Schulz-Knappe P. (Eds). Peptidomics in Drug Development (2005), Editio Cantor, Aulendorf, Germany 109-133
128. Lee K., Yim E., Kim C., Namkoong S., Um S., and Park J. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol 98 1 (2005) 45-53
129. Bouchon B., Chambon C., Mounetou E., Papon J., Miot-Noirault E., Gaudreault R., et al. Alkylation of {beta}-tubulin on Glu 198 by a microtubule dirupter. Mol Pharmacol 68 5 (2005) 1415-1422
130. Espina V., Geho D., Mehta A., Petricoin III E., Liotta L., and Rosenblatt K. Pathology of the future: Molecular profiling for targeted therapy. Cancer Invest 23 1 (2005) 36-46
131. Skvortsov S., Sarg B., Loeffler-Ragg J., Skvortsova I., Lindner H., Werner Ott H., et al. Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Mol Cancer Ther 3 12 (2004) 1551-1558
132. Poland J., Wandschneider S., Urbani A., Bernardini S., Federici G., and Sinha P. Use of proteomics to study chemosensitivity. Methods Mol Med 111 (2005) 267-281
133. Urbani A., Poland J., Bernardini S., Bellincampi L., Biroccio A., Schnolzer M., et al. A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 5 3 (2005) 796-804
134. Iwadate Y., Sakaida T., Saegusa T., Hiwasa T., Takiguchi M., Fujimoto S., et al. Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int J Oncol 26 4 (2005) 993-998
135. Righetti P., Castagna A., Antonucci F., Piubelli C., Cecconi D., Campostrini N., et al. Proteome analysis in the clinical chemistry laboratory: Myth or reality?. Clin Chim Acta 357 2 (2005) 123-139
136. Shin Y., Yoo B., Chang H., Jeon E., Hong S., Jung M., et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65 8 (2005) 3162-3170
137. Allal A., Kahne T., Reverdin A., Lippert H., Schlegel W., and Reymond M. Radioresistance-related proteins in rectal cancer. Proteomics 4 8 (2004) 2261-2269
138. Gaenshirt D., and Harms F. The role of peptidomics in drug development. In: Gaenschirt D., Harms F., Rohmann S., and Schulz-Knappe P. (Eds). Peptidomics in Drug Development (2005), Editio Cantor, Aulendorf, Germany 109-133
139. Heike Y., Hosokawa M., Osumi S., Fujii D., Aogi K., Takigawa N., et al. Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res 25 2B (2005) 1197-1203
140. Fella K., Gluckmann M., Hellmann J., Karas M., Kramer P., and Kroger M. Use of two-dimensional gel electrophoresis in predictive toxicology: Identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis. Proteomics 5 7 (2005) 1914-1927
141. Kang M., Lee D., Joo W., and Kim C. Plasma protein level changes in waste incineration workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Proteome Res 4 4 (2005) 1248-1255